Compare WYY & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WYY | ANIX |
|---|---|---|
| Founded | 1991 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.8M | 88.8M |
| IPO Year | 2005 | 2013 |
| Metric | WYY | ANIX |
|---|---|---|
| Price | $10.75 | $2.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $8.67 | $8.67 |
| AVG Volume (30 Days) | ★ 144.6K | 100.0K |
| Earning Date | 05-14-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.82 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $150,545,364.00 | $210,000.00 |
| Revenue This Year | $14.41 | N/A |
| Revenue Next Year | $11.41 | N/A |
| P/E Ratio | $1,127.00 | ★ N/A |
| Revenue Growth | ★ 5.59 | N/A |
| 52 Week Low | $2.80 | $2.44 |
| 52 Week High | $12.25 | $5.46 |
| Indicator | WYY | ANIX |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 33.67 |
| Support Level | $4.76 | $2.44 |
| Resistance Level | N/A | $3.13 |
| Average True Range (ATR) | 1.20 | 0.14 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 59.88 | 2.56 |
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.